Ocumension Therapeutics (HKSE:01477) EBIT per Share : HK$-0.42 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics EBIT per Share?

Ocumension Therapeutics's EBIT per Share for the six months ended in Dec. 2024 was HK$-0.18. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.42.

During the past 3 years, the average EBIT per Share Growth Rate was 15.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Ocumension Therapeutics's EBIT per Share or its related term are showing as below:

HKSE:01477' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -99.5 Med: -10.95 Max: 29.3
Current: 15.2

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Ocumension Therapeutics was 29.30% per year. The lowest was -99.50% per year. And the median was -10.95% per year.

HKSE:01477's 3-Year EBIT Growth Rate is ranked better than
58.66% of 1236 companies
in the Biotechnology industry
Industry Median: 8.1 vs HKSE:01477: 15.20

Ocumension Therapeutics's EBIT for the six months ended in Dec. 2024 was HK$-123.7 Mil.

Ocumension Therapeutics EBIT per Share Historical Data

The historical data trend for Ocumension Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics EBIT per Share Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-8.88

-0.52

-0.71

-0.64

-0.41

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT per Share	Get a 7-Day Free Trial								-0.37	-0.35	-0.29	-0.24	-0.18

Ocumension Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Ocumension Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-283.033	/	683.807
=	-0.41

Ocumension Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-123.684	/	708.412
=	-0.17

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.42

Ocumension Therapeutics (HKSE:01477) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Ocumension Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

5DG:Germany

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

https://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Executives

Liu Ye	2101 Beneficial owner
6 Dimensions Capital, L.p.	2101 Beneficial owner
Zhang Qiping	2201 Interest of corporation controlled by you
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
6 Dimensions Capital Gp, Llc	2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Boyu Capital Fund Iv, L.p.	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iv, Ltd	2201 Interest of corporation controlled by you
Summer Iris Limited	2101 Beneficial owner
Alcon Pharmaceuticals Ltd	2101 Beneficial owner
Alcon Inc.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you

Ocumension Therapeutics Headlines

No Headlines